Seeking Alpha
13 Oct 2026, 20:46 UTC · 1h ago
Johnson & Johnson: Keep Calm And Hold On
Impact · against what's priced in
The latest results for Johnson & Johnson provide no new catalyst, as the beat-and-raise quarter and MedTech progress are already baked into the current valuation. With the market already paying for the operational resilience and the OTTAVA system, the stock remains sensitive to the valuation premiums highlighted by the analyst.
- JNJ+0.00
Already priced in
- The price assumes
The raised 2026 revenue guidance of $100.3–$101.3 billion and adjusted EPS of $11.45–$11.65
The report of a beat-and-raise quarter and resilient sales growth confirms the guidance and trajectory that the market has already factored into the price.
What JNJ's price assumes · Sep 3
Top 1 mover · tap to explore
